Burning Rock Biotech Ltd.
We aim to transform precision oncology and early cancer detection. We are China’s number one NGS-based cancer therapy selection company, as evidenced by the largest market share of 26.7% in China’s NGS-based cancer therapy selection market in terms of number of patients tested in 2019, according to CIC. Our cancer therapy selection platform is built upon our advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model.
|Address||601, 6/F, Building 3, Standard Industrial Unit 2, No.7 Luoxuan 4th Road, International Bio Island, Guangzhou, the People’s Republic of China|
|Phone Number||+86 020-3403 7871|
|View Prospectus:||Burning Rock Biotech Ltd.|
|Revenues||$48.7 mil (last 12 months)|
|Net Income||$-45.0 mil (last 12 months)|
|Price range||$16.50 - $16.50|
|Est. $ Volume||$222.8 mil|
|Manager / Joint Managers||Morgan Stanley/ BofA Securities/ Cowen and Company|
|CO-Managers||CMB International/ Tiger Brokers|
|Expected To Trade:||6/12/2020|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|